Articles Published in 2013

Sticares InterACT receives French research tax credit approval

Monday, August 26, 2013 12:11 PM

Sticares InterACT, an internationally operating contract service provider specializing in cardiovascular and metabolic diseases, has been awarded the French research tax credit approval, which it has been holding since 2009. This approval has now been extended for the years 2013, 2014 and 2015.

More... »

CeMM, Haplogen make collection of human cell lines available

Monday, August 26, 2013 12:09 PM

Haplogen, a biotechnology company developing antiviral therapies, and CeMM, the Center for Molecular Medicine of the Austrian Academy of Sciences, are making available their large collection of human cell lines that are deficient for single genes, which they have been building over the past three years as part of a public-private partnership. The partnership, through Haplogen, will distribute requested cell lines to the research community.

More... »

Amgen to acquire Onyx Pharmaceuticals

Monday, August 26, 2013 12:07 PM

Amgen will acquire San Francisco, Calif.-based Onyx Pharmaceuticals, purchasing all of the outstanding shares of Onyx for $125 per share in cash, for a total purchase price of $10.4 billion, or $9.7 billion net of estimated Onyx cash. The boards of both companies have approved the transaction.

More... »

Nuvilex restructures for biotechnology focus

Friday, August 23, 2013 12:36 PM

Nuvilex, an international biotechnology company and former provider of natural products, as well as cell and gene therapy solutions for the treatment of diseases, has restructured corporate operations in an effort to focus on its biotechnology core businesses.

More... »

Mayo Clinic to open Phoenix stem cell lab

Friday, August 23, 2013 12:32 PM

Mayo Clinic in Arizona will open its own stem cell laboratory in summer 2014. The laboratory will be initially dedicated to storing and processing stem cells used for bone marrow transplants at Mayo Clinic Hospital and Phoenix Children's Hospital.

More... »

Shire, Santaris extend collaboration to discover and develop LNA-drugs

Friday, August 23, 2013 12:29 PM

Santaris Pharma, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, has announced that its long-term partner, Shire, has extended the existing partnership in the rare genetic disease space.  

More... »

Takeda expands to Peru

Friday, August 23, 2013 12:22 PM

Zurich-based Takeda Pharmaceuticals International has further expanded its presence in Latin America with the launch of a wholly-owned subsidiary in Peru. Takeda Peru S.R.L. will be headquartered in Lima and will be responsible for the sales and marketing of Takeda's products in Peru.

More... »

Vical restructures, 39% staff reduction

Friday, August 23, 2013 12:15 PM

Vical, which researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases, has announced a restructuring to conserve capital, including a staff reduction of 47 employees, approximately 39% of the company's total workforce. Following the restructuring, the company will have approximately 74 employees. In addition, the company is focusing its resources on its infectious disease vaccine programs and terminating activities related to Allovectin, the company's investigational cancer immunotherapy which recently failed to meet its phase III efficacy endpoints.

More... »

Pediatric auditory brainstem implant clinical trial awarded NIH grant

Friday, August 23, 2013 11:48 AM

House Research Institute (HRI) and Los Angeles Children’s Hospital have announced final approval of grant funding by the NIH National Institute on Deafness and Communications Disorders (NIDCD) for a five-year, FDA-approved clinical trial of the auditory brainstem implant (ABI) in children.

More... »

Decision Resources suggests breast cancer market to reach $15B by 2022

Friday, August 23, 2013 11:39 AM

Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of premium-priced agents will fuel 5% annual growth in the breast cancer market, with sales reaching more than $15 billion in 2022 in the U.S., France, Germany, Italy, Spain, the U.K. and Japan.

More... »